Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
For patients with IDH mutant 1p/19q codeleted LGG tumors, there is limited evidence to support the use of TMZ.
|
31701682 |
2020 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mutation of the isocitrate dehydrogenase (IDH) gene is regarded a novel indicator for the prognosis of patients with glioma.
|
31746408 |
2020 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
T1+Gad performed best for IDH typing of glioblastoma (sensitivity 91.9%, specificity 100%, AUC 0.945) and ADC for non-Gadolinium-enhancing gliomas (sensitivity 85.7%, specificity 78.4%, AUC 0.877).
|
30927935 |
2019 |
Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of the study was to determine the pathological and genetic characteristics of lower-grade gliomas that carry IDH2 mutations.
|
31833906 |
2019 |
Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
IDH Mutation Analysis in Glioma Patients by CADMA Compared with SNaPshot Assay and two Immunohistochemical Methods.
|
29556922 |
2019 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
IDH Inhibitors Target Common Glioma Mutation.
|
31217295 |
2019 |
Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutation of the isocitrate dehydrogenase (IDH) gene and co-deletion on chromosome 1p/19q is becoming increasingly relevant for the evaluation of clinical outcome in glioma.
|
30529899 |
2019 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Results</b>: We found that PD-L2 expression level was significantly upregulated in higher grade glioma and IDH wild-type glioma.
|
30713802 |
2019 |
Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
<sup>18</sup>F-DOPA uptake does not correlate with IDH mutation status and 1p/19q co-deletion in glioma.
|
30607877 |
2019 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A nomogram incorporating radiomics signature, IDH and age improved the performance of OS estimation, which might be a new complement to the treatment guidelines of glioma.
|
31606714 |
2019 |
Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
<sup>1</sup> H-MRS enables non-invasive detection of 2-hydroxyglutarate (2-HG), an oncometabolite accumulating in gliomas carrying mutations in the isocitrate dehydrogenase (IDH) genes.
|
30457203 |
2019 |
Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There is variability in survival within IDH mutant gliomas determined by chromosomal events.
|
31134296 |
2019 |
Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recent DNA methylation analyses revealed a small group of IDH mutant diffuse gliomas exhibiting decreased DNA hypermethylation resulting in substantial unfavorable prognosis comparable to glioblastoma.
|
30937703 |
2019 |
Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PCR-sequencing (n = 220), immunohistochemistry staining (IHC, n = 220), and gas chromatography mass spectrometry (GC-MS, n = 87) were applied to identify IDH mutation in gliomas, and the sensitivity and specificity of these strategies were compared.
|
30573870 |
2019 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CD163 expression was up-regulated in IDH wild-type glioma and mesenchymal subtype.
|
31143523 |
2019 |
Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers.
|
31222125 |
2019 |
Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In clinical samples of gliomas with IDH1 mutation, levels of D-2-hydroxyglutarate (D-2HG) were increased significantly compared with gliomas without IDH mutation.
|
31278288 |
2019 |
Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multivariate analysis incorporating tumor status based on the presence of <i>IDH</i> mutations, <i>TERT</i> promoter mutations, and 1p/19q codeletion showed that in lower-grade gliomas, high NLR predicted poorer survival for the triple-negative, IDH mutation only, TERT mutation only, and IDH and TERT mutation groups.
|
31444316 |
2019 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Podoplanin Expression and IDH-Wildtype Status Predict Venous Thromboembolism in Patients with High-Grade Gliomas in the Early Postoperative Period.
|
31100523 |
2019 |
Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the isocitrate dehydrogenase (IDH) enzyme affect 40% of gliomas and represent a major diagnostic and prognostic marker.
|
29126125 |
2018 |
Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In contrast, tumor grade and presence of chromosome 1p/19q codeletion in the IDH mutated glioma could not be predicted from the level of 2-HG.
|
29671246 |
2018 |
Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Methylation-mediated miR-155-FAM133A axis contributes to the attenuated invasion and migration of IDH mutant gliomas.
|
29885519 |
2018 |
Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The latest 2016 WHO 2016 revision now includes molecular data such as IDH mutation and 1p/19q codeletion thus restructuring glioma classification.
|
29258767 |
2018 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression level of B7-H3 was consistently up-regulated in IDH wild-type glioma and highly enriched in mesenchymal subtype.
|
30377558 |
2018 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Molecular profiling of different glioma specimens from an Ollier disease patient suggests a multifocal disease process in the setting of IDH mosaicism.
|
30159860 |
2018 |